Literature DB >> 6425421

Ability of monomeric peptidoglycan fragments from Neisseria gonorrhoeae to damage human fallopian-tube mucosa.

M A Melly, Z A McGee, R S Rosenthal.   

Abstract

Purified disaccharide peptide monomers obtained from Neisseria gonorrhoeae by enzymatic digestion of gonococcal peptidoglycan damaged the mucosa of human fallopian tubes in organ culture. Two peptidoglycan fragments were tested: a nonreducing, anhydromuramyl-containing monomer (the principal fragment shed by growing gonococci) and the analogous reducing, muramidase-derived monomer. The damage produced by either of these peptidoglycan monomers resulted in sloughing of ciliated cells from the mucosa and resembled the damage observed in active gonococcal infection and that produced by filter-sterilized toxic supernatant fluids from gonococcal-infected organ cultures. The minimal toxic dose of peptidoglycan monomers was 0.75 micrograms/ml. Neither lipopolysaccharide, sodium dodecyl sulfate, nor Triton X-100, possible contaminants from the monomer-purification procedures, was present in sufficient quantity to account for the damage. Both of the gonococcal peptidoglycan monomers may be present in vivo and thus may play a role in the pathogenesis of gonococcal infection.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6425421     DOI: 10.1093/infdis/149.3.378

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  75 in total

1.  Neisseria gonorrhoeae PBP3 and PBP4 Facilitate NOD1 Agonist Peptidoglycan Fragment Release and Survival in Stationary Phase.

Authors:  Ryan E Schaub; Krizia M Perez-Medina; Kathleen T Hackett; Daniel L Garcia; Joseph P Dillard
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

2.  Mutations affecting peptidoglycan acetylation in Neisseria gonorrhoeae and Neisseria meningitidis.

Authors:  Joseph P Dillard; Kathleen T Hackett
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Mutation of a single lytic transglycosylase causes aberrant septation and inhibits cell separation of Neisseria gonorrhoeae.

Authors:  Karen A Cloud; Joseph P Dillard
Journal:  J Bacteriol       Date:  2004-11       Impact factor: 3.490

4.  Dual strategies for peptidoglycan discrimination by peptidoglycan recognition proteins (PGRPs).

Authors:  Chittoor P Swaminathan; Patrick H Brown; Abhijit Roychowdhury; Qian Wang; Rongjin Guan; Neal Silverman; William E Goldman; Geert-Jan Boons; Roy A Mariuzza
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-09       Impact factor: 11.205

5.  AtlA functions as a peptidoglycan lytic transglycosylase in the Neisseria gonorrhoeae type IV secretion system.

Authors:  Petra L Kohler; Holly L Hamilton; Karen Cloud-Hansen; Joseph P Dillard
Journal:  J Bacteriol       Date:  2007-05-25       Impact factor: 3.490

Review 6.  The molecular mechanisms used by Neisseria gonorrhoeae to initiate infection differ between men and women.

Authors:  Jennifer L Edwards; Michael A Apicella
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Mutations in ampG and lytic transglycosylase genes affect the net release of peptidoglycan monomers from Vibrio fischeri.

Authors:  Dawn M Adin; Jacquelyn T Engle; William E Goldman; Margaret J McFall-Ngai; Eric V Stabb
Journal:  J Bacteriol       Date:  2008-12-12       Impact factor: 3.490

8.  Analysis of damage to human ciliated nasopharyngeal epithelium by Neisseria meningitidis.

Authors:  D S Stephens; A M Whitney; M A Melly; L H Hoffman; M M Farley; C E Frasch
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

9.  Role of Major Toxin Virulence Factors in Pertussis Infection and Disease Pathogenesis.

Authors:  Karen Scanlon; Ciaran Skerry; Nicholas Carbonetti
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

10.  Attachment of pathogenic Neisseria to human mucosal surfaces: role in pathogenesis.

Authors:  D S Stephens; Z A McGee; M A Melly; L H Hoffman; C R Gregg
Journal:  Infection       Date:  1982       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.